Summer 2026
Sales Operations & Analytics Intern
Posted on 2/27/2026
Calyxo
201-500 employees
Develops and markets kidney stone devices
Compensation Overview
$28 - $32/hr
Pleasanton, CA, USA
In Person
 Data & Analytics (1) |
|---|
- Education: Current junior or senior pursuing a bachelor’s degree in Business, Analytics, Data Science, Economics, Finance, Healthcare Administration, Information Systems, or a related field
- Work Location: Pleasanton, CA
- Travel: Minimal (~5%)
- Fulltime employment
- Technical Skills: Proficiency in Microsoft Excel (pivot tables, formulas, data analysis)
- Familiarity with Microsoft Office (PowerPoint, Word)
- Core Competencies: Strong attention to detail
- Core Competencies: Excellent verbal and written communication skills
- Core Competencies: Ability to analyze data and solve problems
- Core Competencies: Ability to manage multiple projects and adapt to change
- Core Competencies: Eagerness to learn, ask questions, and take ownership
- Core Competencies: Ability to work independently and collaboratively in a team environment
- Support data quality and customer intelligence initiatives, including physician-to-account mapping, data cleansing, and identification of data gaps or inconsistencies across Salesforce and related systems
- Analyze commercial programs and investments to assess utilization, effectiveness, and potential return, providing insight to Sales and Finance leadership
- Partner with Sales Operations and field leadership to gather requirements and support the development of Tableau dashboards used for territory management, performance tracking, and coaching
- Assist in evaluating Tableau Next and Salesforce embedded analytics business cases, including benchmarking available data, assessing data readiness, and identifying high-impact reporting opportunities
- Conduct research and analysis on sales workflows, reporting processes, and analytics best practices to identify opportunities for efficiency and improvement
- Collaborate cross-functionally with Sales, Marketing, Finance, and IT to support commercial operations initiatives
- Prepare summary analyses, presentations, and documentation for leadership review
- Perform other duties as required
- Exposure to Salesforce, Tableau, or other analytics and CRM platforms
- Coursework or experience in data analytics, business intelligence, or operations
- Interest in healthcare, medical devices, or commercial strategy
Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.
Company Size
201-500
Company Stage
Series F
Total Funding
$137.2M
Headquarters
Pleasanton, California
Founded
2016
Simplify's Take
What believers are saying
- Calyxo raised $40 million in Series F from specialist healthcare investors.
- CVAC crossed 40,000 kidney stone procedures, strengthening physician referenceability.
- Funding supports commercial expansion and health-economic evidence generation.
What critics are saying
- Boston Scientific already owns installed ureteroscopy franchises in most hospitals.
- A 2024 MAUDE report documented sepsis and death after CVAC use.
- Calyxo still depends on early evidence; larger studies can narrow differentiation.
What makes Calyxo unique
- CVAC continuously aspirates stone fragments during and after laser lithotripsy.
- FDA cleared CVAC in March 2024, lowering regulatory friction.
- ASPIRE showed superior stone clearance and lower residual stone volume versus URS.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Calyxo who can refer or advise you
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Stock Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 2%2 year growth
↑ 8%Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.
PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups
PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)
Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.
Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.